trending Market Intelligence /marketintelligence/en/news-insights/trending/x2_QOKc8qAymGGvot8IlQg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

China approves launch of Roche's Perjeta for breast cancer


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

China approves launch of Roche's Perjeta for breast cancer

China's National Medical Products Administration approved the importation of Roche Holding AG's Perjeta as a treatment for HER2-positive breast cancer, in combination with Herceptin and chemotherapy.

Perjeta, also known as pertuzumab, works by preventing the human epidermal growth factor receptor 2, or HER2, from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the immune system to destroy cancer cells.

Herceptin, also marketed by Roche, was included in China's national drug reimbursement list in 2017.

SNL Image